



NDA 21-572/S-014

Cubist Pharmaceuticals, Inc.
Attention: David S. Manus, PhD
Vice President, Regulatory Affairs
65 Hayden Avenue
Lexington, MA 02421

Dear Dr Mantus:

Please refer to your supplemental new drug application dated March 23, 2007, received March 26, 2007 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for CUBICIN[®] (daptomycin for injection) 500 mg/vial.

This "Changes Being Effected" supplemental new drug application provides for revisions to the package insert to include information relative to recent epidemiologic and scientific data regarding *Clostridium difficile* associated disease (CDAD).

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on March 23, 2007.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Katherine A. Laessig, MD
Deputy Director
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Labeling submitted on March 23, 2007

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Kathrine Laessig
10/5/2007 02:59:08 PM